Literature DB >> 27437645

Treatment of Heart Failure With Preserved Ejection Fraction: Reflections on Its Treatment With an Aldosterone Antagonist.

Marc A Pfeffer1, Eugene Braunwald1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27437645     DOI： 10.1001/jamacardio.2015.0356

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  10 in total

Review 1.  How to Develop and Implement a Specialized Heart Failure with Preserved Ejection Fraction Clinical Program.

Authors:  Sanjiv J Shah; Rebecca Cogswell; John J Ryan; Kavita Sharma
Journal:  Curr Cardiol Rep       Date:  2016-12       Impact factor: 2.931

2.  Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease.

Authors:  Mohammad Saud Khan; Muhammad Shahzeb Khan; Abdelmoniem Moustafa; Allen S Anderson; Rupal Mehta; Sadiya S Khan
Journal:  Am J Cardiol       Date:  2019-11-19       Impact factor: 2.778

Review 3.  Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.

Authors:  Ravi B Patel; Sanjiv J Shah; Gregg C Fonarow; Javed Butler; Muthiah Vaduganathan
Journal:  Curr Heart Fail Rep       Date:  2017-08

4.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2021-05-22

Review 5.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; James Thomas; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28

6.  Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease.

Authors:  Lauren B Cooper; Steven J Lippmann; Melissa A Greiner; Abhinav Sharma; Jacob P Kelly; Gregg C Fonarow; Clyde W Yancy; Paul A Heidenreich; Adrian F Hernandez
Journal:  J Am Heart Assoc       Date:  2017-12-23       Impact factor: 5.501

7.  Long-term Prognostic Value of Estimated Plasma Volume in Heart Failure with Preserved Ejection Fraction.

Authors:  Chen-Yu Huang; Ting-Tse Lin; Yi-Fan Wu; Fu-Tien Chiang; Cho-Kai Wu
Journal:  Sci Rep       Date:  2019-10-07       Impact factor: 4.379

8.  Machine learning can predict survival of patients with heart failure from serum creatinine and ejection fraction alone.

Authors:  Davide Chicco; Giuseppe Jurman
Journal:  BMC Med Inform Decis Mak       Date:  2020-02-03       Impact factor: 2.796

9.  Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.

Authors:  Gerasimos Filippatos; Bertram Pitt; Rajiv Agarwal; Dimitrios Farmakis; Luis M Ruilope; Peter Rossing; Johann Bauersachs; Robert J Mentz; Peter Kolkhof; Charlie Scott; Amer Joseph; George L Bakris; Stefan D Anker
Journal:  Eur J Heart Fail       Date:  2022-05-19       Impact factor: 17.349

10.  Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial.

Authors:  Subha V Raman; Kan N Hor; Wojciech Mazur; Xin He; John T Kissel; Suzanne Smart; Beth McCarthy; Sharon L Roble; Linda H Cripe
Journal:  Orphanet J Rare Dis       Date:  2017-02-20       Impact factor: 4.303
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.